معرفی
Sin-Ho Jung is a Professor of Biostatistics & Bioinformatics at Duke University and a member of the Duke Cancer Institute and Division of Integrative Genomics. His research integrates advanced statistical methodologies with critical biomedical applications, particularly in oncology and diagnostic development.
Education:
- Ph.D. in Biostatistics, University of Wisconsin, Madison (1992)
Research Interests: Dr. Jung specializes in clinical trial design (especially phase II/III cancer trials), survival analysis for time-to-event data, longitudinal and clustered data analysis, ROC curve methodology for diagnostic accuracy, and high-dimensional genomic data analysis. His work bridges theoretical statistics with practical implementation in cancer research, biomarker validation, and big data applications, emphasizing methodological rigor for real-world clinical impact.
Publication Trends: Recent publications (2024-2025) demonstrate sustained focus on statistical innovation for oncology trials, including group-treatment trial designs, ROC curve comparisons, and high-dimensional prediction modeling. Key themes involve optimizing trial efficiency, validating biomarkers, and developing robust methods for survival and diagnostic data, reflecting deep integration of biostatistics with translational cancer research.
Scientific Awards:
- No scientific awards mentioned in source text
Advising and Grants: Dr. Jung teaches BIOSTAT 907: Phase II Clinical Trials and mentors graduate students in biostatistics methodology. His extensive grant portfolio includes 10 active NIH-funded projects:
- A Phase II, Multi-centre, Randomised, Double-blind, Group Comparator Trial to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Patients with Tenosynovial Giant Cell Tumour (SynOx Therapeutics Ltd, 2025-2030)
- Disparate Survival, Disparate Workforce: An Integrated Approach to Improving Head and Neck Cancer Outcomes and Diversity in the Oncology Workforce (NIDCR, 2024-2029)
- Cascade Amplification Biosensor Technology for Detecting MicroRNA Biomarkers of Alzheimer Disease (NIA, 2025-2027)
- Harnessing treatment-induced tumor evolution and collateral sensitivities using a human rectal cancer co-clinical platform (NCI, 2022-2027)
- Integrated Biostatistical Training for CVD Research (NC State, 2022-2027)
- RAPID System for Early Detection of Head and Neck Cancer in Low-Resource Settings (NIH, 2022-2027)
- Detecting missed metastases from nominally early-stage melanomas with pump-probe microscopy (USAMRAA, 2023-2026)
- Home-based Autologous Hematopoietic Stem Cell Transplantation to Improve Outcomes and Decrease Costs (KUMC, 2025-2026)
- Improving Accuracy of Next-Generation Microscopy for Early Stage Metastatic Melanoma Detection (NCI, 2024-2025)
- Prebiotics to Optimize the Microbiota and Improve Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (KUMC, 2024-2025)
Labs and Teams: As a member of the Duke Cancer Institute and Division of Integrative Genomics, Dr. Jung collaborates with multidisciplinary teams spanning oncology, genomics, and biomedical engineering to translate statistical innovations into clinical applications, particularly in cancer diagnostics and therapeutic development.
